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Background: Access to good-quality medicines in many countries is largely hindered by the rampant circulation of
spurious/falsely labeled/falsified/counterfeit (SFFC) and substandard medicines. In 2006, the Ministry of Health of
Cambodia, in collaboration with Kanazawa University, Japan, initiated a project to combat SFFC medicines.
Methods: To assess the quality of medicines and prevalence of SFFC medicines among selected products, a
cross-sectional survey was carried out in Cambodia. Cefixime, omeprazole, co-trimoxazole, clarithromycin, and
sildenafil were selected as candidate medicines. These medicines were purchased from private community drug
outlets in the capital, Phnom Penh, and Svay Rieng and Kandal provinces through a stratified random sampling
scheme in July 2010.
Results: In total, 325 medicine samples were collected from 111 drug outlets. Non-licensed outlets were more
commonly encountered in rural than in urban areas (p < 0.01). Of all the samples, 93.5% were registered and
80% were foreign products. Samples without registration numbers were found more frequently among
foreign-manufactured products than in domestic ones (p < 0.01). According to pharmacopeial analytical results,
14.5%, 4.6%, and 24.6% of the samples were unacceptable in quantity, content uniformity, and dissolution test,
respectively. All the ultimately unacceptable samples in the content uniformity tests were of foreign origin.
Following authenticity investigations conducted with the respective manufacturers and medicine regulatory
authorities, an unregistered product of cefixime collected from a pharmacy was confirmed as an SFFC medicine.
However, the sample was acceptable in quantity, content uniformity, and dissolution test.
Conclusions: The results of this survey indicate that medicine counterfeiting is not limited to essential medicines in
Cambodia: newer-generation medicines are also targeted. Concerted efforts by both domestic and foreign
manufacturers, wholesalers, retailers, and regulatory authorities should help improve the quality of medicines.
Keywords: Quality of medicine, Spurious/falsely labeled/falsified/counterfeit (SFFC) medicine, Authenticity,
Essential medicine, CambodiaBackground
Spurious/falsely labeled/falsified/counterfeit (SFFC) medi-
cines are deliberately and fraudulently mislabeled with re-
spect to identity or source [1,2]. Falsifying is greatest in
those regions where regulatory and legal oversight is weak-
est. Although precise, detailed data on SFFC medicines are
difficult to obtain, estimates range from less than 1% of
sales in developed countries to over 10% in developing* Correspondence: naoko@p.kanazawa-u.ac.jp
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unless otherwise stated.countries, depending on the geographic area [3]. Several
reports have documented adverse health consequences
from consumption of SFFC medicines. More than 200 chil-
dren died in a hospital in Bangladesh through ingesting
SFFC paracetamol, which contained diethylene glycol, in
1990–93 [4]. In 1998, 30 infants died from SFFC para-
cetamol in India [5]. In Southeast Asia in 2001, 38% of
104 anti-malaria drugs were found to be SFFC [6]. In
Cambodia in 1999, at least 30 people died through SFFC
artesunate containing sulfadoxine-pyrimethamine, which is
an older, less effective anti-malarial [5]. In 2005, a man
aged 23 years treated with SFFC artesunate died in easternl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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taking fake anti-diabetic medicines containing illegal quan-
tities of glibenclamide in China; in 2008, four people died
in Singapore after taking an SFFC phosphodiesterase type
5 inhibitor containing glibenclamide [8,9]. In addition to
SFFC products, substandard and degraded medicines are
classified as poor-quality medicines [10]. Substandard med-
icines are genuine medicines produced by legitimate man-
ufacturers that do not meet the quality specifications
declared by the producer [11]. Degraded products may re-
sult from exposure of good-quality medicines to light, heat,
and humidity; however, it can be difficult to distinguish de-
graded medicines from those that left the factory as sub-
standard [12]. Substandard and degraded medicines reduce
the effectiveness of therapy.
In Cambodia, the Ministry of Health (MoH) reported
in 2001 that 13% of medicines were SFFC, with 21% be-
ing substandard and 50% unregistered [13]; in the same
country, 35 medicines were found to be SFFC among
142 products in 2004 [14]. Furthermore, in our previous
study in Cambodia in 2006–09, we identified 19 SFFC
products among life-saving essential medicines [15,16].
Evidence suggests that lack of awareness and inappropri-
ate management in the supply chain could facilitate the
distribution of SFFC medicines in the country [17].
To oppose the threat of SFFC medicines and prevent
their spread, the Department of Drugs and Food (DDF)
of the MoH has been conducting surveillance on the
quality of medicines since 2006. In 2010, we selected
some newer-generation medicines, including antibiotics,
to assess falsifying trends in the context of this develop-
ing country. At the same time, we sought to identify the
influential factors in falsifying practices and develop a




Samples were collected from the capital, Phnom Penh
(urban area), and Svay Rieng and Kandal provinces (rural
areas). The list of licensed outlets in Phnom Penh was
obtained from the DDF, MoH of Cambodia, in June
2013. The calculated sample size was 193 pharmacies,
58 depot A outlets, and 79 depot B outlets, with an
alpha value of 5 and power of 0.8. In Phnom Penh, as
many private drug outlets as possible of the four types of
private drug outlets (i.e., pharmacies, depot A, depot B,
and non-licensed outlets) were visited within the period
of sample collection. For sampling purposes, a stratified
random scheme developed by means of random number
tables was used. All the outlets found in Svay Rieng and
all illegal outlets found in the sampling area were visited.
Additionally, some samples were collected from whole-
salers and drug outlets in Kandal province while thesampling teams moved between Phnom Penh and Svay
Rieng. In Cambodia, a pharmacy outlet is run by a regis-
tered pharmacist, a depot A outlet by an assistant pharma-
cist (with 4 years’ pharmacy training), and a depot B outlet
by a retired midwife or nurse [17]. The sampling areas
were selected in consultation with the MoH, taking into
account the degree of urbanization, population density,
concentration of drug outlets, budgetary limitations, and
geographic importance in sharing a border with another
country.
Sample collection
Cefixime tablets, omeprazole capsules, co-trimoxazole (a
combination of sulfamethoxazole and trimethoprim) tab-
lets, clarithromycin tablets, and sildenafil tablets were se-
lected as candidate medicines in consultation with the
DDF. Cefixime, omeprazole, clarithromycin, and sildenafil
were chosen in 2010 as newer-generation medicines; this
was in contrast to selection from a list of essential medi-
cines in our previous studies [15,16]. Sample information
was collected using a sampling form that included the
contents of the packages sold, price, and outlet informa-
tion. Samples were collected between June 7 and 15, 2010
by two teams. Each team consisted of a research investiga-
tor, a locally recruited sampling officer, and a sampling as-
sistant. The locally recruited members were provided with
training before sampling and instructed to purchase medi-
cines. The sampling officer purchased medicines in an
outlet and completed a sampling form for each sample.
Medicines collected from the same outlet and labeled with
the same international non-proprietary name, brand
name, strength, size, batch/lot number, and manufacturing
and expiry dates were considered one sample. For authen-
tication purposes, the teams collected containers or pack-
ages for most of the samples. Samples were preserved at
20–25°C until analysis.
Observation test
Details of the packaging condition and the label infor-
mation of the samples were carefully noted. Compliance
with the Association of Southeast Asian Nations Common
Technical Dossier (ACTD) for the registration of pharma-
ceuticals for human use (to which drug registration in
Cambodia conforms) was examined [18]. Bar codes were
also recorded.
Materials for quality evaluation
United States Pharmacopeia (USP) reference standards
of omeprazole, sulfamethoxazole, trimethoprim, and
clarithromycin-related compound A (6,11-di-o-methyl
erythromycin A) were purchased from the Reference
Standard Center, Bureau of Drugs and Narcotics,
Thailand (Nonthaburi, Thailand). Reference standards
of cefixime, clarithromycin, and sildenafil citrate were
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Japan), Taisho Toyama Pharmaceutical Co, Ltd. (Tokyo,
Japan), and Pfizer Japan Inc. (Tokyo, Japan), respectively.
Metronidazole and butyl p-hydroxy benzoate were pur-
chased from Nacalai Tesque, Inc. (Kyoto, Japan). Primi-
done and sulfadoxine were purchased from Wako Pure
Chemical Industries, Ltd. (Osaka, Japan). Lansoprazole was
purchased from Sigma-Aldrich Co. LLC (St. Louis, MO,
USA). Methanol and acetonitrile of high-performance li-
quid chromatography (HPLC) grade was purchased from
Nacalai Tesque, Inc. (Kyoto, Japan). All other chemicals
were commercially available and of analytical grade.
Quality evaluation
The Medicine Quality Assessment Reporting Guide-
lines (MEDQUARG) were followed when reporting in
generally [10].
To assess the pharmaceutical quality of the samples, ac-
tive ingredients of the samples were quantified by HPLC
using ultraviolet detection (Shimadzu, Kyoto, Japan). The
system suitability for analysis of each medicine was veri-
fied according to USP 30. A linear relationship between
the peak area and concentration of each reference stand-
ard was observed within the range of 25–200% of the
active ingredient (r2 = 0.999–1.000), and the assay was per-
formed within that range. The intra- and inter-day coeffi-
cient of variation was less than 3.0%. In addition, the
methods were validated as being repeatable and accurate
(n = 6). Metronidazole, butyl p-hydroxybenzoate, primi-
done, lansoprazole, and sulfadoxine were used as internal
standards in the analysis of cefixime, clarithromycin, co-
trimoxazole, omeprazole, and sildenafil, respectively. The
samples were analyzed between July 2010 and March
2012 in Kanazawa University. The quality evaluation was
completed within the expiry date for each sample.
For cefixime tablets, omeprazole capsules, co-trimoxazole
tablets, and clarithromycin tablets, the assay, a content
uniformity test, and dissolution test were performed
with reference to USP 30, USP34, or British Pharmaco-
peia (BP) 2010 as indicated on the package insert or
outer package.
For sildenafil tablets, the assay was performed accord-
ing to the method described previously [19]. In each
sample, three or six tablets were analyzed. The accept-
able range was set as follows: in the quantity test, silden-
afil tablets containing not less than 90% and not more
than 110% on an average quantity taken from 10 units,
and no unit less than 75% or more than 125% of the la-
beled amount of sildenafil; in the dissolution test, the ac-
ceptable range was an average dissolution rate in 3 or 6
units equal to or greater than 75% and no unit less than
50%, with a dissolution time of 15 minutes. The content
uniformity test could not be conducted because of insuf-
ficient material.Authenticity investigation
The methodology of the authenticity investigation and
registration verification was adopted from the World
Health Organization [15,16,20,21]. Label information on
the packages and containers was cross-checked with a
database prepared after collection. Photographs of each
sample, its packaging, and package inserts were obtained
for such purposes. These data were then catalogued. A
database of manufacturer addresses was also prepared
using printed information, Web searches, and e-mail and
telephone communication. Portions of all samples were
then sent to the respective manufacturers, requesting veri-
fication of their products. Information on the manufac-
turers and their medicines was requested from medicine
regulatory authorities of the countries in which the manu-
facturing took place. Furthermore, each sample’s registra-
tion was confirmed by the DDF.
Statistical analysis
Considering the limitations of the small sample size, de-
scriptive analysis was performed using SPSS 19.0.0 (IBM
SPSS Inc, Chicago, IL, USA). Where appropriate, Fisher’s
exact test was used to test the significance of categorical
variables. Statistical significance was evaluated at the 5%
level.
Results
Table 1 presents an outline of the samples. We collected
a total of 325 samples from 111 drug outlets (including
14 wholesalers) in the study area. Of these, 60 (18.5%)
were cefixime, 48 (14.8%) were clarithromycin, 91 (28.0%)
were omeprazole, 44 (13.5%) were sildenafil, and 82 (25.2%)
were co-trimoxazole. Of the samples, 237 (72.9%) were
collected from Phnom Penh and 88 (27.1%) from the
provinces: 81 (24.9%) from Svay Rieng and seven (2.2%)
from Kandal. Foreign products constituted the majority
(80%) of the total samples. Local manufacture was com-
monest for co-trimoxazole (48/82 samples).
Drug outlets
Of the 325 samples, we collected 108 (33.2%) from phar-
macies, 62 (19.1%) from depot A outlets, 92 (28.3%) from
depot B outlets, 32 (9.8%) from wholesalers, and 31 (9.5%)
from non-licensed outlets. We found non-licensed outlets
significantly more frequently in rural (33.0%, 29/88) than
in urban areas (0.8%, 2/237) (Fisher’s exact test: p < 0.01).
Pharmacists were present in 72.4% (21/29) of the pharma-
cies. All 14 wholesalers but only one pharmacy had air
conditioning.
Observations
We observed differences in package design (layout and/
or printed colors) in four products—one each of cefix-
ime and clarithromycin and two kinds of omeprazole—
Table 1 Outline of the samples
Sampling area Shop category Country of manufacturer
Urban Rural Pharmacy Depot A Depot B Wholesaler Non-licensed outlet Domestic Imported
Cefixime (n = 60) 42 18 20 10 19 6 5 4 56
Clarithromycin (n = 48) 36 12 17 10 15 4 2 10 38
Co-trimoxazole (n = 82) 58 24 21 16 28 7 10 48 34
Omeprazole (n = 91) 63 28 26 21 24 8 12 2 89
Sildenafil (n = 44) 38 6 24 5 6 7 2 0 44
Total (n = 325) 237 88 108 62 92 32 31 64 261
Table 3 Language of package inserts
Language n (%)
Yoshida et al. BMC Pharmacology and Toxicology 2014, 15:13 Page 4 of 8
http://www.biomedcentral.com/2050-6511/15/13from the same lot number. With eight products—two
kinds of cefixime, three kinds of clarithromycin, one co-
trimoxazole, and two kinds of omeprazole—we observed
a different package design with different lot numbers.
Except for nine samples, ACTD requirements (which
were fully implemented in early 2011) appeared in the
information on the packaging. Six of those samples
lacked lot numbers and manufacturing and expiry dates
on their packaging. With three of those samples, the
packaging did not include a manufacturing date. The
registration number did not appear on the outer pack-
aging with some samples (Table 2). One sample of cefix-
ime bore a false lot number, had two spelling errors, and
was confirmed as an SFFC medicine in the authenticity
investigation.
About 80% (264/325) of the samples included a European
Article Number code, which is a bar-code symbol used in
supply chain management. However, 61 products had nei-
ther a European Article Number code nor a GS1 DataBar™
symbol (GS1, Brussels, Belgium), which can carry more in-
formation and be used to identify small items.
We observed varying degrees of discrepancies in com-
pliance with ACTD in the information that appeared in
package inserts (Tables 3 and 4). We collected package
inserts from 106 products (284 samples, 87.4%). The
package inserts of 102 products (87.2%) were written in
English and/or Khmer and/or French: all these languages
are officially accepted in Cambodia. However, four prod-
ucts were written in Vietnamese only (Table 3). Table 4
shows other discrepancies with the package inserts of 87




n (%) n (%)
Batch number 313 (98.1) 6 (1.9)
Manufacturing date 310 (97.2) 9 (2.8)
Expiration date 313 (98.1) 6 (1.9)
Registration number 304 (95.3) 15 (4.7)
n = 319 samples.dosage, and administration were described for all products
(Table 4). One package insert failed to stipulate contrain-
dications, two did not state precautions, and two did not
indicate side effects; one product lacked all three of these
items (Table 4). With over 10% of the products, informa-
tion relating to clinical pharmacology (23 products), drug
interactions (11 products), pregnancy and lactation (12
products), overdose and treatment (33 products), and stor-
age conditions (20 products) was not provided (Table 4).
The date of revision of the package insert was not given
for 79 products (90.8%). Six (6.9%) products satisfied the
items required by ACTD, whereas 55 (63.2%) products
had missing data for multiple elements.
We collected products that were unregistered or lacked
lot numbers, manufacturing dates, expiry dates, or regis-
tration numbers (in at least one item) from illegal outlets
(7/24) more frequently than from legal ones (15/279)
(Fisher’s exact test: p < 0.05). However, the sampling area
and origin of the samples were not statistically associated
as acceptable findings.
Pharmaceutical quality
Among the 325 samples analyzed for their contents, 47
(14.5%) were of unacceptable quality (Table 5). Of 281
samples, we finally determined that 15 (4.6%) were un-
acceptable in content uniformity tests. In dissolution
tests, which were not obligatory for registration in 2010
in Cambodia, 80 (24.6%) samples were unacceptable.Khmer only 1 (0.9)
English only 74 (63.2)
English and Khmer 5 (4.3)
Khmer and other language 11 (9.4)
English and other language 8 (6.8)
French only 3 (2.6)
Vietnamese only 4 (3.4)
Unavailable 11 (9.4)
Total 117 (100.0)
Table 4 Information on package inserts
Items required by ACTD Presence Absence
n (%) n (%)
Clinical pharmacology 64 (73.6) 23 (26.4)
Indications 87 (100.0) 0 (0.0)
Dosage and administration 87 (100.0) 0 (0.0)
Contraindications 86 (98.9) 1 (1.1)
Warnings and precautions 85 (97.7) 2 (2.3)
Drug interactions 76 (87.4) 11 (12.6)
Pregnancy and lactation 75 (86.2) 12 (13.8)
Side effects 85 (97.7) 2 (2.3)
Overdose and treatment 54 (62.1) 33 (37.9)
Storage conditions 67 (77.0) 20 (23.0)
Date of revision 8 (9.2) 79 (90.8)
n = 87 products, whose package inserts were written in English.
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281 samples) in the content uniformity tests were of
foreign origin and were registered products. Of the 64
domestic samples, 21 were unacceptable for one or more
of the quality tests.
Authenticity
We received authentication reports from 49 of 75 (65.3%)
manufacturers for 230 (71%) samples and 5 of 11 (45.5%)
medicine regulatory authorities. On the basis of authenti-
city results, we confirmed one sample of cefixime as an
SFFC medicine (Figure 1). The sample product was not
registered in Cambodia; it was labeled with batch number
976213, manufactured date 11/2009, and expiry date 10/
2011. The product was purchased from a pharmacy, and
it came from an unknown wholesaler. The sample passed
quantity, content uniformity, and dissolution test.
Of the 325 samples, 309 (95.1%) were registered by the
DDF and 16 (4.9%) were not registered. Six samples of
unregistered medicines were sold with labels indicating
that they were registered. Two of these samples were





Accepted Unaccepted Pending Acce
Cefixime 60 56 3 1 5
Clarithromycin 48 44 4 0 4
Co-trimoxazole 82 73 9 0 8
Omeprazole 91 54 22 15 3
Sildenafil 44 32 9 3
Total 325 259 47 19 2
Pending: samples pending at time of decision because of insufficient material.centers) only; however, they were purchased from pharma-
cies. All 16 samples of such illegal medicines were
imported products.
Discussion
The results of this survey indicate a number of problems
in the manufacturing and distribution conditions, qual-
ity, and packaging of medicines in Cambodia. Among
111 drug outlets we visited, including wholesalers, only
one pharmacy in Phnom Penh and all 14 wholesalers had
air conditioning in their storage areas. Despite temperature
rises above 40°C in the dry season in Cambodia, the other
drug outlets did not have any temperature-control mea-
sures [22]. Storing medicines at high temperature and
humidity could result in deterioration of quality and might
facilitate the distribution of degraded medicines in the
market [23-25]. In Cambodia, good pharmacy practice, dis-
tribution practice, and storage practice have not been im-
plemented. Hence, the deterioration in quality may be due
to storage or distribution. To prevent the distribution of
degraded products, storage conditions at drug outlets need
to be better controlled. To this end, good pharmacy prac-
tice will be introduced in Cambodia by the end of 2013.
Following quality evaluation of the collected samples,
we found that some products had problems in their outer
packaging, such as different colors and/or layout for the
same product, spelling errors, and a lack of identification
codes. These discrepancies may have resulted from insuffi-
cient awareness of the risks and countermeasures adopted
by legitimate manufacturers against SFFC or substandard
medicines. Such shortcomings could make it more diffi-
cult to distinguish SFFC medicines, and dealing with this
problem should help prevent the entry of such products
into the market. Additionally, the circulation of unregis-
tered medicines and unauthorized distribution of pub-
licly donated ones could affect the emergence of SFFC
medicines in the supply chain. The SFFC medicine we
detected in this survey—cefixime tablets bearing a false
lot number—did not have Cambodian registration, bore
spelling errors on the label, and was obtained at a
pharmacy. Nevertheless, we found the sample to beContent uniformity test Dissolution test
pted Unaccepted Pending Accepted Unaccepted Pending
5 0 5 51 3 6
2 1 5 27 11 10
1 0 1 65 15 2
1 14 46 42 45 4
- - - 28 6 10
09 15 57 213 80 32
Figure 1 Bottle and label for SFFC cefixime sample.
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ution tests according to USP 30. Cefixime, an oral third-
generation cephalosporin, has excellent therapeutic action
against infections caused by bacteria and is relatively high
in price. Counterfeiters thus have an incentive in produ-
cing such antibiotics [26]. This is possibly the first report
of SFFC cefixime in Cambodia. The findings of this
survey indicate that not only are earlier-generation,
commonly used essential medicines targeted by coun-
terfeiters, newer-generation medicines are similarly
falsified because of a better profit margin. Sildenafil, a
newer-generation medicine, is a medicine that is more
likely to be counterfeited in developed countries [27].
The present study shows that sildenafil had low distri-
bution, and no counterfeit product was found. This
finding suggests that the target medicine for counter-
feiting may vary depending on the country.
In the pharmaceutical quality evaluation of the 325
samples we identified, 103 (31.7%) were unacceptable in
one or more of the quantity, content uniformity, and dis-
solution tests. Most of those were enteric-coated omepra-
zole capsules, which especially showed an unacceptably
high failure ratio in the dissolution test. Unacceptable
samples in the dissolution test for omeprazole may have
resulted from poor enteric coating, which could cause
degradation of the omeprazole by gastric acid and lead to
ineffectiveness after oral administration. Variables related
to formulation or manufacturing processes of medicines
can significantly affect dissolution and the expected med-
ical effects. Consequently, some pharmaceutical manufac-
turers, mainly from overseas, may not have attained thenecessary technical level to produce enteric preparations.
To maintain the quality of medicines, exporting countries
should not allow substandard medicines to be exported to
other developing countries. Furthermore, each manu-
facturer selects its specifications among existing phar-
macopoeias and in-house specifications; thus, for some
medicines, the conditions in dissolution testing are dif-
ferent between USP and BP standards. Indeed, it would
be desirable for the MoH to define uniform requirements
for dissolution testing. In early 2011, the MoH began
implementing the dissolution test for registration; there
was, however, no focus on this issue before 2011. Thus,
samples collected in 2010 may have been particularly sub-
ject to problems with the dissolution test. Since dissol-
ution testing has been added as a mandatory requirement
for registering medicines in Cambodia, the situation may
improve in the near future. Furthermore, the lack of infor-
mation in package inserts and non-compliance with lin-
guistic requirements of the ACTD could hinder the safe,
proper use of medicines. Having adequate information on
the packaging and inserts could minimize the misuse of
medicines and reduce therapeutic failure [28,29]. For
package inserts, three languages—French, English, and
Khmer—are officially accepted in Cambodia. To en-
courage the proper use of medicines, some key words
have been translated into Khmer by the MoH for prod-
ucts lacking Khmer instructions. Essentially, the con-
tents of all package inserts need to be translated into
Khmer from French or English. Furthermore, ACTD
was implemented in Cambodia only at the end of 2010.
Before 2008, there was no checking and verification of
all registered products by design and brand name. There-
fore, the MoH has carried out such checking and verifica-
tion only since 2008. However, products registered before
2008 can be distributed and sold as usual until their
licenses expires; it is not until the papers relating to such
products are submitted for license renewal that the ACTD
requirements come into effect. ACTD was fully imple-
mented in early 2011.
Printing technology has improved and become widely
available to the point where SFFC medicines are able to
show very close similarity to original products [21,30].
Even medical practitioners may fail to spot SFFC medi-
cines in their practices. Stopping SFFC medicines from
entering the market is one way of preventing consumers
being subjected to the health hazards associated with
such medicines.
Toward creating a healthy, secure system for pharma-
ceutical distribution, it is likewise imperative to stop SFFC
medicines from entering the market. Improved regulation
of illegal medicines, revision and compliance of existing
rules for pharmaceuticals, and introducing a pharmaceut-
ical traceability system could help ensure the circulation
of genuine medicines.
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representative of conditions throughout Cambodia be-
cause of the limited area of sample collection, insufficient
sample size in the stratified random sampling in Phnom
Penh, and convenient sampling of some samples from se-
lected drug outlets. Additionally, we did not receive re-
sponses relating to the authenticity investigation from 26
manufacturers; therefore, we were unable to confirm 95
samples as having been genuine or SFFC. Because of the
insufficient number of samples, we could not verify the
status of 43 medicines in our quality evaluation. These
limitations make it difficult to assess the actual extent of
SFFC and substandard medicines in the entire Cambodian
supply chain.
Conclusions
In conclusion, the results of this survey indicate that
medicine falsifying is not limited to essential medicines in
Cambodia: newer-generation medicines are also targeted.
Concerted efforts by manufacturers—both domestic and
overseas—along with those by wholesalers, retailers, and
regulatory authorities are necessary to ensure the quality
of medicines.
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